| Previous Close | 1.59 |
| Open | 1.59 |
| Bid | 1.56 x 8000 |
| Ask | 1.69 x 200 |
| Day's Range | 1.58 - 1.67 |
| 52 Week Range | 1.20 - 8.22 |
| Volume | 912,442 |
| Avg. Volume | 848,510 |
| Market Cap | 121.88M |
| Beta | 1.12 |
| PE Ratio (TTM) | -1.84 |
| EPS (TTM) | -0.89 |
| Earnings Date | Aug 7, 2017 - Aug 11, 2017 |
| Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.65 |
- Business Wire•19 days ago
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
Arrowhead Pharmaceuticals, Inc. today announced that as an inducement to entering into employment with the Company, on June 5, 2017, eleven new employees were awarded "inducement" grants of options under Rule 5635 of the NASDAQ Marketplace Rules.
- Capital Cube•last month
ETFs with exposure to Arrowhead Pharmaceuticals, Inc. : May 26, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Arrowhead Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to ARWR-US. Comparing the performance and risk of Arrowhead Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of ARWR earnings conference call or presentation 3-May-17 8:30pm GMT
Q2 2017 Arrowhead Pharmaceuticals Inc Earnings Call